Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands by Anneloes L. Noordhof, MD, Esther M. Swart, MSc, Ronald A.M. Damhuis, PhD, Lizza E.L. Hendriks, MD, PhD, Peter W.A. Kunst, MD, PhD, Mieke J. Aarts, PhD, Wouter H. van Geffen, MD, PhD

Get full text